Carnosine

L-carnosine

Grade B: Human evidence, not approved for this use

TL;DR: Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide found in muscle and brain tissue, and it has a meaningful body of published human trial data, making it the best-evidenced compound in this chunk. Multiple randomized, placebo-controlled trials have examined it in metabolic contexts, including glucose regulation in adults with prediabetes and type 2 diabetes, with some trials showing favorable effects on fasting glucose, insulin resistance, and glycation end products, while others found no significant change in inflammatory markers. A recent RCT from the NEAT trial program reported cognitive improvements in younger participants. Trial sizes have generally been small to modest, and results across outcomes are mixed rather than uniformly positive. The compound is also extensively studied via its precursor beta-alanine for muscle carnosine loading and exercise performance, which is a distinct but related evidence strand. Long-term safety trials beyond several months are limited. Cognitive findings are mixed: a benefit appeared mainly in the youngest subgroup in one trial, and a separate randomized trial in prediabetes and type 2 diabetes found no cognitive effect.

Key Takeaways

Grade B: Human evidence, not approved for this use
Not FDA approved: Not an FDA-approved drug; marketed as a dietary supplement in the US; associated precursor beta-alanine has Self-Affirmed GRAS status under at least one branded formulation.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

Endogenous dipeptide that functions as an intracellular buffer, antioxidant, and anti-glycation agent, with proposed roles in reducing oxidative stress and advanced glycation end-product formation in muscle and neural tissue.

Evidence

Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide found in muscle and brain tissue, and it has a meaningful body of published human trial data, making it the best-evidenced compound in this chunk. Multiple randomized, placebo-controlled trials have examined it in metabolic contexts, including glucose regulation in adults with prediabetes and type 2 diabetes, with some trials showing favorable effects on fasting glucose, insulin resistance, and glycation end products, while others found no significant change in inflammatory markers. A recent RCT from the NEAT trial program reported cognitive improvements in younger participants. Trial sizes have generally been small to modest, and results across outcomes are mixed rather than uniformly positive. The compound is also extensively studied via its precursor beta-alanine for muscle carnosine loading and exercise performance, which is a distinct but related evidence strand. Long-term safety trials beyond several months are limited. Cognitive findings are mixed: a benefit appeared mainly in the youngest subgroup in one trial, and a separate randomized trial in prediabetes and type 2 diabetes found no cognitive effect.

Safety and risks

Carnosine is a naturally occurring dipeptide present in dietary meat and has been sold as a supplement for decades with a favorable short-term safety profile. A recent controlled study in healthy volunteers found it was well tolerated at doses up to several grams per day. The compound is not associated with serious adverse events in published trial data. Minor transient effects have occasionally been noted. Long-term safety data beyond a few months of supplementation are sparse. Individuals with histidine or imidazole sensitivity should exercise caution, though this has not been formally characterized in clinical populations. The mixed metabolic findings (some null results on glucose and inflammation) mean benefit is not assured, but the short-term safety signal is more reassuring than most research peptides on this site.

Interactions

No formally documented drug interactions; theoretical caution with drugs affecting histamine metabolism given the histidine component, though clinically significant interactions have not been reported in trials.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

Carnosine is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).